CervoMed Statistics
Total Valuation
CervoMed has a market cap or net worth of $103.75 million. The enterprise value is $51.28 million.
Important Dates
The next estimated earnings date is Monday, November 11, 2024, before market open.
Earnings Date | Nov 11, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
CervoMed has 8.25 million shares outstanding. The number of shares has increased by 35.96% in one year.
Shares Outstanding | 8.25M |
Shares Change (YoY) | +35.96% |
Shares Change (QoQ) | +41.04% |
Owned by Insiders (%) | 35.20% |
Owned by Institutions (%) | 24.41% |
Float | 3.89M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 7.85 |
Forward PS | 19.77 |
PB Ratio | 2.04 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 5.31 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.73
Current Ratio | 14.73 |
Quick Ratio | 14.03 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | n/a |
Return on Capital (ROIC) | n/a |
Revenue Per Employee | $1.21M |
Profits Per Employee | -$630,410 |
Employee Count | 8 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +19.71% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | +19.71% |
50-Day Moving Average | 15.21 |
200-Day Moving Average | 16.85 |
Relative Strength Index (RSI) | 40.92 |
Average Volume (20 Days) | 76,413 |
Short Selling Information
The latest short interest is 1.18 million, so 14.30% of the outstanding shares have been sold short.
Short Interest | 1.18M |
Short Previous Month | 1.15M |
Short % of Shares Out | 14.30% |
Short % of Float | 30.33% |
Short Ratio (days to cover) | 12.40 |
Income Statement
In the last 12 months, CervoMed had revenue of $9.65 million and -$5.04 million in losses. Loss per share was -$0.82.
Revenue | 9.65M |
Gross Profit | 1.21M |
Operating Income | -9.95M |
Pretax Income | -5.04M |
Net Income | -5.04M |
EBITDA | n/a |
EBIT | -9.95M |
Loss Per Share | -$0.82 |
Full Income Statement Balance Sheet
Cash & Cash Equivalents | 45.09M |
Total Debt | n/a |
Net Cash | 50.90M |
Net Cash Per Share | $6.17 |
Equity (Book Value) | 49.98M |
Book Value Per Share | 6.06 |
Working Capital | 44.11M |
Full Balance Sheet Cash Flow
Operating Cash Flow | -7.63M |
Capital Expenditures | n/a |
Free Cash Flow | -7.63M |
FCF Per Share | -$0.92 |
Full Cash Flow Statement Margins
Gross margin is 12.58%, with operating and profit margins of -103.03% and -52.24%.
Gross Margin | 12.58% |
Operating Margin | -103.03% |
Pretax Margin | -52.24% |
Profit Margin | -52.24% |
EBITDA Margin | n/a |
EBIT Margin | -103.03% |
FCF Margin | -35.85% |
Dividends & Yields
CervoMed does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -35.96% |
Shareholder Yield | -35.96% |
Earnings Yield | -4.94% |
FCF Yield | -7.47% |
Analyst Forecast
The average price target for CervoMed is $57.60, which is 358.23% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $57.60 |
Price Target Difference | 358.23% |
Analyst Consensus | Strong Buy |
Analyst Count | 5 |
Revenue Growth Forecast (5Y) | 38.70% |
EPS Growth Forecast (5Y) | 70.71% |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
CervoMed has an Altman Z-Score of 15.64 and a Piotroski F-Score of 2.
Altman Z-Score | 15.64 |
Piotroski F-Score | 2 |